We are live on
!
Find out more
MAM
MPM Asset Management Portfolio holdings
AUM
$44.5M
1-Year Est. Return
47.28%
This Fund
S&P 500
This Quarter
Est. Return
+1.79%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$204M
AUM Growth
-$36.1M
(-15%)
Cap. Flow
-$37.5M
Cap. Flow
% of AUM
-18.39%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
–
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$7.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
|
+$38.9M |
| 2 |
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
|
+$6.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
WCPI
BAM
WAMC
NLVP
CIEP
IPI
CC
VSAM
MPM Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, MPM Asset Management held 10 positions worth $204M, down 15% from $240M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MPM Asset Management withdrew a net $37.5M in Q2 2023, closing 2 positions. Its most notable exit was Amryt Pharma plc American Depositary Shares, an estimated $38.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM Asset Management opened a new position in Adaptimmune Therapeutics worth $5.82M.
- MPM Asset Management's largest Q2 2023 buy was Adaptimmune Therapeutics: 6,287,101 shares worth $5.82M.
- MPM Asset Management fully exited Amryt Pharma plc American Depositary Shares in Q2 2023, selling an estimated $38.9M.
- MPM Asset Management's ten largest holdings make up 100% of its $204M portfolio in Q2 2023.
- MPM Asset Management opened 1 new position and closed 2 in Q2 2023.
- MPM Asset Management's portfolio value fell 15% quarter-over-quarter to $204M.
Based on MPM Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.